Switching From Mounjaro to Wegovy in Bromley: A Clear, Patient-Friendly Guide for 2026

Switching from Mounjaro to Wegovy in Bromley: Safer, Cheaper, Clearer Options in 2026

Considering a switch from Mounjaro to Wegovy in Bromley? Understand how they work, who is eligible, the latest UK price context, pros and cons, and how our West Wickham clinic supports you.

Why patients in Bromley are asking about switching now

I’m seeing more people across Bromley, West Wickham, Beckenham, Croydon, Orpington, Lewisham and Catford asking whether it’s sensible to switch from Mounjaro (tirzepatide) to Wegovy (semaglutide). The reasons are very practical: changing prices, NHS eligibility differences, and individual tolerance.

In August, Lilly confirmed a large UK list-price rise for Mounjaro from September 2025, with the highest monthly dose moving from about £122 to £330 for the private market; the company also noted that NHS pricing is separate, so NHS patients are not expected to be affected. Reuters

By contrast, Wegovy access and messaging on the NHS has been stable since launch, and the government’s health blog plus NHS pages set out who may qualify and how access works within specialist weight-management pathways. Health Media+1

So yes—Wegovy is generally the cheaper private option right now for many doses, and with stronger clarity on NHS pathways. If you’re weighing up a switch, this guide explains the “what, why, and how” in plain English.

Want a broader starter overview? Read our guide: Start Weight Loss Injections.

The science in simple terms: Mounjaro vs Wegovy

Both medicines are weekly injections that help you feel satisfied with smaller portions and support steady weight loss alongside healthy habits.

• Mounjaro (tirzepatide) acts on two hormones (GLP-1 and GIP). In major trials, people lost around 20–21% of body weight at higher doses over ~72 weeks when used with lifestyle support. New England Journal of Medicine+1

• Wegovy (semaglutide) acts on one hormone (GLP-1). STEP-program trials reported ~15–17% average weight loss over ~68 weeks with lifestyle support. New England Journal of Medicine+1

Both are clinically proven. Mounjaro’s dual-hormone action often delivers more weight loss on average, but Wegovy remains highly effective and, in the current UK private market, often more affordable. For many patients, Wegovy’s benefit–tolerability–cost balance makes it a strong option in 2025.

For official context on access and safe use, see NHS England’s medicines for obesity page and NHS obesity treatment guidance. NHS England+1

Pros and cons when considering a switch

I’ll keep this tight, because lists should help—not overwhelm.

Potential reasons to switch to Wegovy

• Cost pressure on private Mounjaro users after the Sept 2025 price rise. Reuters

• Clear NHS pathways for semaglutide and established clinic processes in England. Health Media+1

• Strong efficacy backed by large STEP trials and long clinical experience. New England Journal of Medicine+1

Reasons you might stay on Mounjaro

• You’ve already achieved excellent weight loss and tolerability and prefer not to change what’s working. SURMOUNT evidence and real-world use support continued benefit. New England Journal of Medicine

• In some individuals, dual-agonist therapy may feel more potent. (Response is personal; results vary.)

Shared considerations

• Both are weekly, prescription-only, and most effective with lifestyle support.

• Side-effects can be similar (nausea, reflux, constipation/diarrhoea) and usually ease as your body adapts.

• Monitoring is essential; we adjust dose and pacing to reduce side effects and keep you safe.

Who can switch—and how we plan it safely

If you’re in Bromley or South London and thinking about switching, we follow a structured plan at Bromley Travel & Weight Loss Clinic (Lakewood Pharmacy):

1. Clinical review: medical history, current dose, side-effects, weight-loss progress, goals.

2. Washout or timed transition: depending on your current tirzepatide dose and tolerability, we agree a sensible gap or timed switch to semaglutide to avoid over-exposure or stacking effects.

3. Dose selection: we typically start Wegovy low and step up steadily, mirroring NHS specialist practice to minimise GI issues.

4. Follow-ups: check-ins at agreed intervals to assess weight change, appetite, side-effects and adherence.

NHS pages emphasise that medicines for obesity should be prescribed within structured services, with multi-disciplinary support. That’s exactly how we work, even in private care: measured, supportive, and safe. NHS England

Cost context in 2025: what’s really changed

• Mounjaro private list price: highest doses rising from ~£122 to £330 per month from September 2025; NHS pricing is under a separate deal so NHS patients are not expected to be affected. Reuters

• Wegovy: long-standing NHS guidance and availability through specialist services, alongside private access with clearer supply stability compared to 2023’s launch period. Health Media

If you’re paying privately and the budget matters, Wegovy often becomes the more economical weekly option after the September change, while still offering robust 15–17% average weight loss in trials. New England Journal of Medicine

For local NHS updates on tirzepatide availability and criteria evolution, regional ICBs (e.g., Sussex) have provided public notes on phased roll-out for people with obesity and multiple co-morbidities. Criteria and pathways can differ by region and service capacity, so we’ll always check locally. NHS Sussex+1

Data at a glance (kept simple)

• Efficacy

  • Mounjaro (tirzepatide): ~20–21% average weight loss at higher doses over ~72 weeks. Financial Times

  • Wegovy (semaglutide): ~15–17% average over ~68 weeks. New England Journal of Medicine

• Dosing

  • Both: once weekly, with gradual dose escalation to balance effect and tolerability (your prescriber sets the pace). (General dosing practice reflected across NHS guidance for medicines for obesity.) NHS England

• Access

  • NHS: Prescribed via specialist services under eligibility rules (BMI thresholds and co-morbidities). NHS England+1

  • Private: Available following clinical assessment; prices vary by dose and supplier. (Government blog also explains access expectations for Wegovy.) Health Media

Real experiences and community voices

It can help to hear from others on similar journeys. UK discussions on Wegovy and Mounjaro appear in active Reddit threads. They’re anecdotal, not medical advice, but they give a sense of lived experience and day-to-day tips from users across the country:

• Wegovy personal reflections (Reddit UK): https://www.reddit.com/r/unitedkingdom/comments/1i0agfu/i_feel_blessed_to_get_wegovy_weightloss_jab_but/

• Mounjaro eligibility chat (r/MounjaroUK): https://www.reddit.com/r/mounjarouk/comments/1lj47ii/mounjaro_now_on_nhs_but_the_eligibility_criteria/

What to expect if you switch with us in West Wickham

At Bromley Travel & Weight Loss Clinic at Lakewood Pharmacy, 108 High St, West Wickham BR4 0ND, we’ll walk you through the change step by step. I’ll explain how Wegovy works, when to take it, how to inject safely, what to do if you feel queasy, and how we’ll scale the dose. We’ll also keep the focus on simple lifestyle habits—small changes that you can actually stick to.

Opening hours
Monday–Friday 8:30am–6:30pm
Saturday 9am–4pm · Sunday Closed
📞 020 8916 9610

Prefer to plan online? Book now: https://bromleyweightloss.clinic/booking

FAQs about switching from Mounjaro to Wegovy

Will I lose less weight on Wegovy than I did on Mounjaro?
Possibly—but not always. On average, tirzepatide studies report higher weight loss than semaglutide. However, individual responses vary a lot. Some patients do just as well on Wegovy, especially with consistent habits. New England Journal of Medicine+1

Is Wegovy cheaper now than Mounjaro for private patients?
For many doses, yes—especially after the Sept 2025 Mounjaro list-price rise. We’ll talk you through current pricing and any supply agreements we can access. Reuters

Can I get Wegovy on the NHS in Bromley?
Eligibility is strict and routed through specialist weight-management services. We can help you understand local pathways and whether a referral makes sense. NHS England+1

Do I need a gap between stopping Mounjaro and starting Wegovy?
Often we plan a timed transition or short gap depending on dose and side-effects. We’ll decide together at your consultation to keep you safe and comfortable (reflecting the structured approach used in NHS services). NHS England

Will side-effects be different?
They can feel similar—nausea, reflux, constipation or diarrhoea—but many settle with dose titration. Tell us how you’re feeling; we can slow escalation, give practical tips, and support you.

Do I have to change my diet and activity?
Yes. Both medicines work best when you make easy, sustainable lifestyle changes. We’ll keep the plan simple and doable.

Helpful resources

• NHS England – Medicines for Obesity (weight-management injections)
  https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ NHS England

• NHS – Obesity treatment overview
  https://www.nhs.uk/conditions/obesity/treatment/ nhs.uk

• Government Health Blog – Accessing Wegovy
  https://healthmedia.blog.gov.uk/2023/09/04/accessing-wegovy-for-weight-loss-everything-you-need-to-know/ Health Media

• Sussex NHS – Tirzepatide (Mounjaro) for weight-loss support (regional update)
  https://www.sussex.ics.nhs.uk/tirzepatide-mounjaro-for-weight-loss-support/ NHS Sussex

Internal reading from our clinic

• Start Weight Loss Injections

• Mounjaro Guide

• Wegovy Guide

How we support Bromley and South London patients

Whether you live in Bromley, West Wickham, Beckenham, Croydon, Orpington, Lewisham or Catford, we aim to keep care personal, affordable, and safe. If cost is the main reason you’re considering a switch, we’ll be open about pricing and do our best to pass on any savings we can access. If tolerability is the driver, we’ll focus on a gentle titration plan with quick access to our team if you feel unwell. And if you’re unsure, we’ll talk it through—no pressure.

Conclusion: Is switching from Mounjaro to Wegovy right for you?

There’s no single right answer. Mounjaro may deliver bigger average weight loss in trials, but Wegovy remains highly effective, broadly available through NHS pathways, and—after the 2025 price change—often more affordable privately. The best choice depends on your goals, budget, side-effects, and local access.

If you’re in Bromley or anywhere in South London, I’d be happy to go through your options in a friendly, private consultation and map out a safe switching plan if that’s the best route for you.

Bromley Travel & Weight Loss Clinic at Lakewood Pharmacy
108 High St, West Wickham BR4 0ND
Phone: 020 8916 9610
Hours: Mon–Fri 8:30am–6:30pm · Sat 9am–4pm · Sun Closed
Book online: https://bromleyweightloss.clinic/booking

Notes on sources:

• UK Mounjaro price rise for private market and NHS not affected: Reuters report, Aug 14, 2025. Reuters

• NHS England medicines for obesity (access pathways, specialist services): official page. NHS England

• Wegovy access (Gov Health Blog 2023) and NHS obesity treatment: official guidance. Health Media+1

• Efficacy: SURMOUNT (tirzepatide ~20–21%); STEP (semaglutide ~15–17%). Financial Times+1